ZYME vs. SVRA, SLN, LYEL, MLYS, PHAR, AVBP, ORIC, PHAT, STOK, and CALT
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Savara (SVRA), Silence Therapeutics (SLN), Lyell Immunopharma (LYEL), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Zymeworks has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Savara has a net margin of 0.00% compared to Zymeworks' net margin of -249.63%. Zymeworks' return on equity of -28.37% beat Savara's return on equity.
92.9% of Zymeworks shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.2% of Zymeworks shares are held by company insiders. Comparatively, 4.6% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Savara had 17 more articles in the media than Zymeworks. MarketBeat recorded 18 mentions for Savara and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.13 beat Savara's score of -0.04 indicating that Zymeworks is being referred to more favorably in the media.
Savara has lower revenue, but higher earnings than Zymeworks. Savara is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Zymeworks currently has a consensus target price of $12.67, suggesting a potential upside of 38.89%. Savara has a consensus target price of $8.80, suggesting a potential upside of 96.43%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Zymeworks.
Savara received 1 more outperform votes than Zymeworks when rated by MarketBeat users. However, 68.59% of users gave Zymeworks an outperform vote while only 65.98% of users gave Savara an outperform vote.
Summary
Savara beats Zymeworks on 9 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
